NASDAQ:HTGM - HTG Molecular Diagnostics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.35 -0.02 (-0.84 %) (As of 05/19/2019 04:00 PM ET)Previous Close$2.35Today's Range$2.28 - $2.4052-Week Range$2.03 - $5.46Volume153,228 shsAverage Volume210,054 shsMarket Capitalization$67.30 millionP/E RatioN/ADividend YieldN/ABeta1.8 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's assay product offerings include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL Cell of Origin Assay; HTG EdgeSeq PATH Assay; HTG EdgeSeq miRNA Whole-Transcriptome Assay; HTG EdgeSeq DLBCL Cell of Origin Assay EU; HTG EdgeSeq ALKPlus Assay EU; HTG EdgeSeq EGFR, KRAS and BRAF Mutation Assay; and HTG EdgeSeq Precision Immuno-Oncology Panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a collaboration agreement with Bristol-Myers Squibb for the development of custom RUO assays; governing agreement with QIAGEN Manchester Limited; development and professional services agreement with Invetech PTY Ltd; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. Receive HTGM News and Ratings via Email Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HTGM Previous Symbol CUSIPN/A CIK1169987 Webwww.htgmolecular.com Phone877-289-2615Debt Debt-to-Equity Ratio0.63 Current Ratio6.30 Quick Ratio6.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$21.50 million Price / Sales3.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book4.20Profitability EPS (Most Recent Fiscal Year)($0.60) Net Income$-16,450,000.00 Net Margins-80.03% Return on Equity-75.50% Return on Assets-37.78%Miscellaneous Employees107 Outstanding Shares28,640,000Market Cap$67.30 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions What is HTG Molecular Diagnostics' stock symbol? HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM." How were HTG Molecular Diagnostics' earnings last quarter? HTG Molecular Diagnostics Inc (NASDAQ:HTGM) posted its earnings results on Thursday, May, 9th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02. The medical research company earned $3.20 million during the quarter, compared to analyst estimates of $2.77 million. HTG Molecular Diagnostics had a negative net margin of 80.03% and a negative return on equity of 75.50%. View HTG Molecular Diagnostics' Earnings History. When is HTG Molecular Diagnostics' next earnings date? HTG Molecular Diagnostics is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for HTG Molecular Diagnostics. What guidance has HTG Molecular Diagnostics issued on next quarter's earnings? HTG Molecular Diagnostics issued an update on its FY 2019 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $23-28 million, compared to the consensus revenue estimate of $29.6 million.HTG Molecular Diagnostics also updated its Q1 2019 guidance to EPS. What price target have analysts set for HTGM? 5 analysts have issued 12-month price objectives for HTG Molecular Diagnostics' shares. Their forecasts range from $5.00 to $8.00. On average, they expect HTG Molecular Diagnostics' stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 187.2% from the stock's current price. View Analyst Price Targets for HTG Molecular Diagnostics. What is the consensus analysts' recommendation for HTG Molecular Diagnostics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for HTG Molecular Diagnostics. What are Wall Street analysts saying about HTG Molecular Diagnostics stock? Here are some recent quotes from research analysts about HTG Molecular Diagnostics stock: 1. According to Zacks Investment Research, "HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. " (5/17/2019) 2. Canaccord Genuity analysts commented, "We reiterate our $5 price target. Q1 beat. Q1/19 revs of $3.2M (-23% Y/Y) beat our $2.6M and the guide of $2.5-3.0M. HTG’s core product revenue of $2.7M (+54%) beat our 1.7ME, and was offset by research revenue of just $0.5M (-78% Y/Y) which was down as two of its active PDP programs are on hold" or paused". Recall that collaboration revenues are lumpy, and HTG drove +56% growth in pharma (PDP) revenue in FY’18. LPS of ($0.19) beat our ($0.26) on lighter spend. HTG now holds $25M of cash on its balance sheet. ILMN amendment. In April, HTG amended its IVD test development agreement with Illumina, for the development and commercialization of RNA or DNA profiling tests for use with ILMN’s MiSeqDx sequencer in oncology diagnostics." (5/14/2019) 3. Cantor Fitzgerald analysts commented, "We reaffirm our OW rating and think HTG’s EdgeSeq offers an attractive workflow solution that addresses key challenges in many existing molecular profiling technologies on the market. We view RNA-based panels as well-positioned to capitalize on trends in biomarker development, including faster turnaround time, lower sample-volume requirement, and next-gen sequencing (NGS)- based testing. We think shares of HTG will be rewarded with consistent product and service revenue acceleration along with a demonstrated growing pipeline of exclusive revenue-generating PDPs." (2/20/2019) 4. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $222M excluding debt. This includes a discounted cash flow analysis based asset value at $231M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate." (12/19/2018) Has HTG Molecular Diagnostics been receiving favorable news coverage? Press coverage about HTGM stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. HTG Molecular Diagnostics earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are some of HTG Molecular Diagnostics' key competitors? Some companies that are related to HTG Molecular Diagnostics include Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), Arrayit (ARYC), Precipio (PRPO), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Pressure Biosciences (PBIO) and PositiveID (PSID). What other stocks do shareholders of HTG Molecular Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Aurinia Pharmaceuticals (AUPH), Idera Pharmaceuticals (IDRA), FleetMatics Group (FLTX), Proteostasis Therapeutics (PTI), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP), Resonant (RESN), Verastem (VSTM), Insys Therapeutics (INSY) and Neovasc (NVCN). Who are HTG Molecular Diagnostics' key executives? HTG Molecular Diagnostics' management team includes the folowing people: Mr. John L. Lubniewski, Pres, CEO & Director (Age 55)Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. & Treasurer (Age 57)Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 66)Dr. Debra A. Gordon, Sr. VP & Chief Legal Counsel (Age 59)Mr. Sam M. Rua Jr., Sr. VP of Regulatory Affairs & Quality Systems (Age 59) When did HTG Molecular Diagnostics IPO? (HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are HTG Molecular Diagnostics' major shareholders? HTG Molecular Diagnostics' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (11.53%), Perkins Capital Management Inc. (2.17%), National Asset Management Inc. (0.79%), TD Asset Management Inc. (0.34%), BlackRock Inc. (0.23%) and Morgan Stanley (0.20%). Company insiders that own HTG Molecular Diagnostics stock include Holdings A/S Novo and Shaun D Mcmeans. View Institutional Ownership Trends for HTG Molecular Diagnostics. Which major investors are selling HTG Molecular Diagnostics stock? HTGM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Acadian Asset Management LLC, National Asset Management Inc., BlackRock Inc., Morgan Stanley and New York State Common Retirement Fund. View Insider Buying and Selling for HTG Molecular Diagnostics. Which major investors are buying HTG Molecular Diagnostics stock? HTGM stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Cowen Prime Services LLC, Charles Schwab Investment Management Inc. and TD Asset Management Inc.. View Insider Buying and Selling for HTG Molecular Diagnostics. How do I buy shares of HTG Molecular Diagnostics? Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is HTG Molecular Diagnostics' stock price today? One share of HTGM stock can currently be purchased for approximately $2.35. How big of a company is HTG Molecular Diagnostics? HTG Molecular Diagnostics has a market capitalization of $67.30 million and generates $21.50 million in revenue each year. The medical research company earns $-16,450,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. HTG Molecular Diagnostics employs 107 workers across the globe. What is HTG Molecular Diagnostics' official website? The official website for HTG Molecular Diagnostics is http://www.htgmolecular.com. How can I contact HTG Molecular Diagnostics? HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615. MarketBeat Community Rating for HTG Molecular Diagnostics (NASDAQ HTGM)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 242 (Vote Outperform)Underperform Votes: 205 (Vote Underperform)Total Votes: 447MarketBeat's community ratings are surveys of what our community members think about HTG Molecular Diagnostics and other stocks. Vote "Outperform" if you believe HTGM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTGM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: How to Invest in a Bull Market Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.